Abstract: The invention relates to materials and procedures for identifying or using tissue factor (TF) pre-mRNA splicing, CIk 1 activity or TF-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mRNAs to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (TF) pre-mRNA splicing in platelets is an indicator of inflammatory and thrombotic disease states. TF pre-mRNA splicing in platelets is correlated with sepsis, increased age (?65), APACHE II score, and bacteremia. Thus, TF mRNA expression patterns in platelets may be used for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation, for example, patients that are at a higher risk for severe sepsis, organ failure, and death.

Abstract: The invention relates to therapeutic target recognition, development, and validation of a compound capable of directly or indirectly modulating TF pre-mRNA splicing in a platelet cell and the use of a platelet TF pre-mRNA splicing modulator for the treatment of a subject suffering from, or thought to be suffering from, disordered coagulation.